Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Have you been paying attention to shares of Veracyte (VCYT) ? Shares have been on the move with the stock up 27.4% over the past month. The stock hit a new 52-week high of $32.86 in the previous session. Veracyte has gained 18.3% since the start of the year compared to the 8.2% move for the Zacks Medical sector and the 6.2% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earning ...

Veracyte (VCYT) delivered second-quarter 2024 adjusted diluted earnings of 30 cents per share, up a stupendous 150% from the year-ago period's level. The reported figure beat the Zacks Consensus Estimate of a loss of 3 cents per share. Revenues Revenues increased 26.7% year over year to $114.4 million, which outpaced the Zacks Consensus Estimate by 14%. Segmental Details Testing revenues totaled $107 million in the reported quarter, up 31% year over year. This rise was mainly due to increased Decipher and A ...

On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million. Testing revenue was $107.0 million, an increase of 31%, driven by the strong performance of our Decipher Prostate and Afirma tests. Total test volume grew to 39,023, an increase of 23% compared to the second quarter of 2023. During the quarter, the company achieved a record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN pros ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 20-5455398 (State or other ...

Veracyte, Inc. (NASDAQ:VCYT) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Mason Carrico – Stephens, Inc. Yuko Oku – Morgan Stanley Maggie Boeye – William Blair Joseph Conway – Needham & Company Prashant Kota – Goldman Sachs Thomas DeBourcy – Nephron Research Operator Good day and thank you for standing by. Welcom ...

Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 1,100%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.19 per share when it actually produced a loss of $0.02, delivering a surprise of 89.47%. Over the last four quar ...

| --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q2 2024 Business and Financial Presentation | | | | | | | | | August 6, 2024 | | | | | | | | Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited ...

Exhibit 99.1 Veracyte Announces Second Quarter 2024 Financial Results Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 6, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024. "Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma," said Marc Stapley, Veracyte's chief exe ...

This molecular diagnostic company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +75%. Revenues are expected to be $100.34 million, up 11.1% from the year-ago quarter. For Veracyte, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VCYT going forward ...